賽里斯治療 MCRB 深 滬
等待開盤 06-25 09:30:00 美东时间
6.81
-0.240
-3.40%
華盛通- 最 高7.27
- 今 開7.02
- 成交量 4.89万股
- 最 低 6.75
- 昨 收 7.05
- 總市值 6594.76万
- 52周最高 29.98
- 市盈率 靜 10.60
- 換手率 0.50%
- 52周最低 5.31
- 委 比 63.64%
- 總股本 968.39万
- 歷史最高 1040.00
- 量 比 0.50
- 振 幅 7.38%
- 歷史最低 5.31
- 每 手 1
- 風險率 4.56%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 美银上调美光科技目标价从950美元升至1500美元，上调迈威尔科技目标价从240美元升至365美元
今日重点评级关注：摩根士丹利：维持杜邦"标配"评级，目标价从52美元升至156美元；蒙特利尔银行：维持Taysha Gene Therapies"跑赢大市"评级，目标价从10美元升至14美元
06-24 14:08
HC Wainwright & Co. Initiates Coverage On Seres Therapeutics with Buy Rating, Announces Price Target of $12
HC Wainwright & Co. analyst Matthew Keller initiates coverage on Seres Therapeutics (NASDAQ:MCRB) with a Buy rating and announces Price Target of $12.
06-23 19:29
Seres Therapeutics Reshapes Finances with Lease Restructuring
An update from Seres Therapeutics ( ($MCRB) ) is now available. On June 2, 2026...
06-05 19:28
Seres Therapeutics Announces Balance Sheet Transactions; Nestle To Pay Company $25 M In Two Installments To Buy Out Sales Milestone Payments
Seres Therapeutics, Inc. (NASDAQ:MCRB), ("Seres" or the "Company"), a leading live biotherapeutics company, today announced two transactions to strengthen its balance sheet and extend its expected operating cash runway
06-05 19:03
Seres Therapeutics amends Vowst deal, secures USD 25 million milestone buyout from Nestlé Health Science
Seres Therapeutics amends Vowst deal, secures USD 25 million milestone buyout from Nestlé Health Science Seres Therapeutics amended its VOWST asset sale agreement with Nestlé Health Science, exchanging potential future net sales milestones for USD 25 million. Payment set in two USD 12.5 million inst
06-05 19:00
Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027
Seres Therapeutics announced two key transactions: a $25 million payment from Nestlé Health Science to buy out future VOWST™ sales milestones and a restructured lease reducing facility costs. The company expects to extend its cash runway into early 2027. Clinical data for SER-155 in immune checkpoint inhibitor-related enterocolitis is anticipated later this month.
06-05 11:00
Seres Therapeutics Q1 EPS $(2.08) Misses $(1.88) Estimate, Sales $358.000K
Seres Therapeutics (NASDAQ:MCRB) reported quarterly losses of $(2.08) per share which missed the analyst consensus estimate of $(1.88) by 10.64 percent. This is a 155.47 percent decrease over earnings of $3.75 per share
05-05 19:14
Seres Therapeutics Presents New Preclinical Data Supporting Design And Potential Of SER-603, Next-Gen Cultivated Live Biotherapeutic Candidate For Inflammatory Bowel Disease, At DDW 2026
Data highlight both SER-603's rational design that targets microbial functions linked to mucosal healing and gastrointestinal inflammation in IBD, as well as the advancement of microbiome-based biomarkers that inform
05-04 19:06
Seres Therapeutics Announces Three Presentations To Take Place At The 2026 European Society Of Clinical Microbiology And Infectious Diseases Global Congress, April 17-21
Presentations DetailsPoster Presentation (Abstract 1726)Title: Effect of investigational, live biotherapeutic, SER-155, on gastrointestinal (GI) microbiome composition in adults receiving allogeneic haematopoietic stem
04-20 19:07
